NeuroSense Therapeutics (NASDAQ:NRSN) Trading Up 0.4% – Should You Buy?

NeuroSense Therapeutics Ltd. (NASDAQ:NRSN)’s share price rose 0.4% during mid-day trading on Monday . The company traded as high as $0.4990 and last traded at $0.4670. 452,053 shares traded hands during trading, an increase of 52% from the average daily volume of 297,059 shares. The stock had previously closed at $0.4652.

Analyst Upgrades and Downgrades

NRSN has been the subject of a number of recent research reports. D. Boral Capital reissued a “buy” rating and issued a $14.00 price objective on shares of NeuroSense Therapeutics in a research note on Wednesday, April 8th. Weiss Ratings cut shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday. One analyst has rated the stock with a Strong Buy rating, two have issued a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, NeuroSense Therapeutics has an average rating of “Moderate Buy” and an average price target of $8.50.

NeuroSense Therapeutics Stock Performance

The company has a market capitalization of $17.64 million, a P/E ratio of -0.86 and a beta of 1.62. The firm’s fifty day moving average is $0.71 and its 200 day moving average is $0.80.

Insider Activity

In other NeuroSense Therapeutics news, CFO Or Eisenberg bought 250,000 shares of the business’s stock in a transaction dated Tuesday, June 16th. The shares were purchased at an average price of $0.80 per share, with a total value of $200,000.00. Following the completion of the purchase, the chief financial officer owned 1,504,050 shares in the company, valued at $1,203,240. This represents a 19.94% increase in their position. The purchase was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Alon Ben-Noon purchased 250,000 shares of NeuroSense Therapeutics stock in a transaction dated Tuesday, June 16th. The stock was acquired at an average price of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the acquisition, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their position. The SEC filing for this purchase provides additional information. 27.40% of the stock is owned by company insiders.

Hedge Funds Weigh In On NeuroSense Therapeutics

A number of large investors have recently bought and sold shares of the business. Yorkville Advisors Global LP bought a new position in NeuroSense Therapeutics in the 4th quarter valued at $77,000. Two Sigma Investments LP purchased a new stake in NeuroSense Therapeutics in the third quarter worth $26,000. Squarepoint Ops LLC lifted its position in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after purchasing an additional 45,450 shares during the last quarter. Finally, Jane Street Group LLC bought a new stake in shares of NeuroSense Therapeutics during the second quarter worth $54,000. Hedge funds and other institutional investors own 1.04% of the company’s stock.

NeuroSense Therapeutics Company Profile

NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.

At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.